P3H4 Promotes Malignant Progression of Lung Adenocarcinoma via Interaction with EGFR
Lung cancer is associated with the greatest number of cancer-related deaths worldwide. Lung adenocarcinoma (LUAD) accounts for 85% of all cases of lung cancer. Despite recent advances in treatment, the 5-year survival rate remains less than 15%. Thus, the diagnostic and therapeutic role of LUAD rema...
Main Authors: | Chen Fang, Yingkuan Liang, Yong Huang, Dong Jiang, Jiaxi Li, Haitao Ma, Lingchuan Guo, Wei Jiang, Yu Feng |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-07-01
|
Series: | Cancers |
Subjects: | |
Online Access: | https://www.mdpi.com/2072-6694/14/13/3243 |
Similar Items
-
Rechallenge with EGFR-TKI after failure of immunotherapy is considered an effective treatment for advanced lung adenocarcinoma patients with EGFR exon 19 deletion: a case report
by: Shubin Chen, et al.
Published: (2023-06-01) -
An Explainable Radiogenomic Framework to Predict Mutational Status of KRAS and EGFR in Lung Adenocarcinoma Patients
by: Berardino Prencipe, et al.
Published: (2023-06-01) -
Prognostic analysis of patients with mutant and wild-type EGFR gene lung adenocarcinoma
by: Zheng H, et al.
Published: (2019-07-01) -
Low-Dose Nicotine Activates EGFR Signaling via α5-nAChR and Promotes Lung Adenocarcinoma Progression
by: Mong-Lien Wang, et al.
Published: (2020-09-01) -
Limited Benefit from the Addition of Immunotherapy to Chemotherapy in TKI-Refractory EGFR-Mutant Lung Adenocarcinoma
by: Lingzhi Hong, et al.
Published: (2022-07-01)